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bolus and infusion had a 36% rate of clinical restenosis (CR). Patients with-
out diabetes had a lower rate of restenosis whether receiving placebo ICR
~ 33%) or c7E3 (CR = 24%). In regression analysis. diabetes was the only
baseline clinical feature associated with an increased event rate (hazard ratio
1.44. P = 0.001). Among patients without diabetes. the relative risk of major
bleeding events was 2.6 times higher for those receiving c7E3 compared
to placebo 19.9% vs. 3.7%. respectively). This effect was doubled among
diabetics (12.9% vs. 2.2%, relative risk = 5.8). In conclusion, these data im-
portantly confirm the higher clinical restenosis among diabetics and demon-
strate a marked propensityto major bleeding events among diabetics treated
with potent platelet antagonists.
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ing In = 21) and prolonged perfusion balloon inflation (PPB; n = 22) as initial
bail-out therapy in failed PTCA. Core lab qualitative and quantitative angiog-
raphy analysis was possible in 40/43 patients.
Results.
Pre randomisation Post Randomisation
MLD{mm) % MLD(mm) % Success Recoil (mm)
5tent 1.1 ± 05 59 ± 17 2.2 ± 0.4 20 + 11 90% 032 ± 035
n ~ 21 19/21
PPB 12 ± 06 60 ± 18 1.5 ± 0.3 46 + 23 42% 096 ± 054
n ~ 19 8/19
P ns ns <0.001 <0.001 0002 <0.001
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1) Stenting was more effective as bail-out therapy (90% vs 42% P < 0.002),
especially in treating dissections of grade C or above: stent 11/12 (91%) vs
PBB (0/5 (0)% P < 0.0001).
2) Angiographic results with successful PPB were inferior to stenting: %
stenosis: 30.6 ± 20.2; MLD 1.9 ± 0.3 (p < 0.05 cf stent MLD) due to greater
recoil in the PPB group: PPB 0.66 ± 0.34 mm Ip < 0.05 cf stent recoil).
3) Stenting following failed PPB was successful in 9/10 attempts with equiv-
alent angiograms results to primary stent bail-out: % stenosis 24.8 ± 8.2;
MLD 2.5 ± 0.4 mm. but procedure time was longer 152.6 ± 53.0 mins v
114.8 ± 31.3 mins (p < 0.05).
Summary. This randomised multicentre study of bailout therapy in failed
PTCA confirms the benefit of stenting in improving immediate results by re-
ducing elastic recoil and sealing complex dissections. Crossover to stenting
following failed PPB gives angiographic results comparable to primary bail-
out stenting at the expense of increased lab time.
AG Results Reference (mm) MLD(mm) % Stenosis
Baseline 3.11 ± 0.47 0.66 ± 0.58 79 ± 19
Post 5tent 309 ± 0.50 3.01 ± 0.47 3 ± 12
Follow Up 3.01 ± 0.48 1.80 ± 0.91 40 ± 28
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TASC II is a randomised multicentre study comparing the strategies of stent-
There was 1 acute stent thrombosis event (1.2%). Restenosis by 50% di-
ameter stenosis criteria was present in 17 of 49 lesions (35%) and 13 of 39
patients (34%).
Conclusions. (1) Stent Implantation in diffuse disease that is assisted by
IVUS is associated with acceptable procedure complication rate and a low
stent thrombosis rate despite the absence of post stent anticoagulation in
the majority of patients. (2) The restenosis rate of 35% appears to represent
an improvement over the reported restenosis rates for diffuse disease after
angioplasty or other devices.
Restenosis After Coronary Angioplasty is
Associated with the Activation Status of
Circulating Phagocytes Before Treatment
De novo Restenosis Total
5 (76) PTCA (73) 5 (61) PTCA (60) 5 {137} PTCA(133)
Death O{O%) 1 a a 0 1
MI 7 1 3 0 10 1
CABG 2 1 0 2 2 3
Repeat
Interven 3 5 5 4 10
Event free
Survival 64 (84%) 65189%) 57 (93%) 53(88%) 121 (88%) 118{89%)
The Trial of Angioplasty and Stents in Canada:
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The trial of angioplasty and stents in Canada (TASC I) compared the strategy
of coronary artery stenting (S) to PTCA in de novo (de N ~ 149) and restenosis
(R ~ 121) lesions with a l' end point of angiographic restenosis and 2' end
point of event free survival at 6 months.
Results:
There was a reduction of clinical events in patients with restenosis le-
sions treated by stenting as compared to de novo lesions: 6.6% vs 15.8%
P ~ 0.094. There was an increased early (less < 40 days) infarct rate in the
stented patients due to stent thrombosis and a trend towards decreased
intervention in target lesions at 6 months (p = 0.088).
Conclusion: The strategies of coronary artery stenting in this study had
equivalent of event free survival to STRESS and Benestent in de novo lesions.
Patients who underwent stenting for restenosis lesions had an improved out-
come with only a 7% cardiac event rate at 6 months.
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Background. The purpose of this study was to identify biological risk factors
for restenosis after PTCA. in order to predict the long-term outcome of PTCA
before treatment.
Methods and Results. To investigate whether blood granulocytes and
monocytes could determine luminal renarrowing after PTCA. several char-
acteristics of these phagocytes were assessed before angioplasty in 32 pa-
tients who underwent PTCA of one coronary artery and who had repeat an-
giograms at six months follow-up. The plasma levels 1L-1 p, TNF-a, IL-6. fib-
rinogen. C-reactive protein and LP(a) before angioplasty were assessed as
well. We found that the expression of the membrane antigens CD64. CD66
and CD67 by granulocytes was inversely associated with the luminal renar-
rowing normalized for vessel size (relative loss) at six months after PTCA.
while the production of IL-1 p by stimulated monocytes was positively asso-
ciated with the relative loss. Next. these univariate predictors were corrected
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Results of Stent Implantation for Diffuse Coronary
Disease Assisted by Intravascular Ultrasound
Mechanism of Benefit of Stenting in Failed PTCA.
Final Results from the Trial of Angioplasty and
Stents In Canada (TASC II)
Luigi Maiello. Patrick Hall. Shigeru Nakamura. Simonetta Blengino. Leo Finci.
Giovanni Martini. Antonio Colombo. Columbus Hospital, Milan. Italy
The long term benefit of elective Palmaz-Schatz stent implantation for fo-
cal lesions in large vessels has been clearly delineated. The elective use of
stents in diffuse disease. however, has not been fully evaluated. This study
reports on the use of stents in 89 pts with 108 lesions (lesl with diffuse dis-
ease. Diffuse disease was defined as a lesion length longer than 20 mm. Af-
ter a successful angiographic result was obtained. intravascular ultrasound
(IVUS) was performed to confirm optimal stent expansion and lesion cover-
age and to guide further balloon dilation and stent implantation. The mean
age was 57 ± 10. Mean lesion length was 32 ± 6 mm. Vessel distribution was
51 LAD (47%). 45 RCA (42%). 10 LCX (9%). and 2 vein graft(2%) Lesion loca-
tion was 49 proximal (45%).52 mid (48%), and 7 distal 17%). 274 stents were
implanted (139 Palmaz-Schatz, 34 short (7 mm) Palmaz-Schatz, 48 Gianturco-
Roubin, and 53 Wiktor) for an average of 2.4 ± 1.4 stentsllesion. Procedure
success was achieved in 83 patients (93%). Procedure associated compli-
cations included 3 myocardial infarction (3%) and 3 emergency bypass (3%)
and 1 elective bypass (1 %). Following the procedure. 77 pts (93%) with 94
les were treated only with anti platelet therapy and no anticoagulation. An-
giographic follow up at 4-6 months was performed on 49 of the eligible 65
lesions (71 %). Baseline. final and follow up angiographic (AG) results are be-
low:
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